{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:36Z","timestamp":1789450116071,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1097\/inf.0000000000000866","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T14:08:27Z","timestamp":1438438107000},"page":"1236-1243","source":"Crossref","is-referenced-by-count":35,"title":["Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults"],"prefix":"10.1097","volume":"34","author":[{"given":"Roger","family":"Baxter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaela","family":"Baine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devayani","family":"Kolhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen I.","family":"Baccarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-18-20210202","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease.","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"R2-18-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease.","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"issue":"RR-2","key":"R3-18-20210202","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"suppl 2","key":"R4-18-20210202","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1086\/648963","article-title":"Epidemiological profile of meningococcal disease in the United States.","volume":"50","author":"Harrison","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R5-18-20210202","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R10-18-20210202","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R11-18-20210202","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults.","volume":"7","author":"Bermal","year":"2011","journal-title":"Hum Vaccin"},{"key":"R12-18-20210202","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4161\/hv.20229","article-title":"Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.","volume":"8","author":"Knuf","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R13-18-20210202","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"R14-18-20210202","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children.","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"R15-18-20210202","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R16-18-20210202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"R17-18-20210202","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial.","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"R18-18-20210202","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-013-0032-5","article-title":"Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.","volume":"30","author":"Findlow","year":"2013","journal-title":"Adv Ther"},{"key":"R19-18-20210202","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-13-116","article-title":"Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.","volume":"13","author":"Borja-Tabora","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R20-18-20210202","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.ijid.2012.10.001","article-title":"Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).","volume":"17","author":"Ostergaard","year":"2013","journal-title":"Int J Infect Dis"},{"key":"R21-18-20210202","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.4161\/hv.22165","article-title":"A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R22-18-20210202","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R23-18-20210202","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4161\/hv.20211","article-title":"The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study.","volume":"8","author":"Dbaibo","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R24-18-20210202","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R25-18-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R26-18-20210202","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/509619","article-title":"Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.","volume":"194","author":"Auckland","year":"2006","journal-title":"J Infect Dis"},{"key":"R27-18-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.8.3.265","article-title":"Prevention of meningococcal serogroup C disease by NeisVac-C.","volume":"8","author":"Borrow","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R28-18-20210202","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/INF.0b013e3181b9a831","article-title":"MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R29-18-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"key":"R30-18-20210202","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/500512","article-title":"Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.","volume":"193","author":"Vu","year":"2006","journal-title":"J Infect Dis"},{"key":"R31-18-20210202","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents.","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"key":"R32-18-20210202","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:08:17Z","timestamp":1620954497000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201511000-00018"}},"subtitle":["An Open, Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000866","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}